Home › Research › Mild cognitive impairment
Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease
Mecocci P, Polidori MC.. Biochimica et biophysica acta, 2011-10-13
Topic: Amyloid, tau and blood-test diagnosis
Alzheimer's disease (AD) is a highly disabling progressive neurodegenerative disorder characterized by a steadily growing number of patients, by the absence of a cure for the disease and by great difficulties in diagnosing in the preclinical phase. Progresses in defining the complex etiopathogenesis of AD consider oxidative stress a core aspect as far as both AD onset and progression are concerned. However, clinical trials of antioxidants in AD have brought conflicting conclusions. In this review, we report the main results of clinical trials with antioxidants in mild cognitive impairment (MCI) and AD. Although available data do not warrant the doubtless use of antioxidants in AD, they are characterized by extremely poor comparability and the absence of a substantial clinical benefit of antioxidants in AD is not disproved to date. Furthermore, the role of vascular damage that contributes to oxidative stress in AD should be addressed in testing antioxidant treatments. This article is part of a Special Issue entitled: Antioxidants and Antioxidant Treatment in Disease.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mecocci, P., & Polidori, M. C. (2012). Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochimica et biophysica acta. https://doi.org/10.1016/j.bbadis.2011.10.006
Vancouver
Mecocci P, Polidori MC. Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochimica et biophysica acta. 2012. doi:10.1016/j.bbadis.2011.10.006. PMID: 22019723.
BibTeX
@article{mecocci2012-22019723,
author = {Mecocci, P. and Polidori, M. C.},
title = {{Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease}},
journal = {Biochimica et biophysica acta},
year = {2012},
doi = {10.1016/j.bbadis.2011.10.006},
pmid = {22019723},
url = {https://doi.org/10.1016/j.bbadis.2011.10.006}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- In this review, we report the main results of clinical trials with antioxidants in mild cognitive impairment (MCI) and AD.
Why it matters
This review of antioxidant trials in MCI and Alzheimer's disease found conflicting results and no substantial clinical benefit, though the data were hard to compare. It does not support the routine use of antioxidants and calls for more research, including on vascular damage.
Study details
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, so that was left out: it earned 40 of the 96 points we could judge it on, which is 42 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Biochimica et biophysica acta) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2012 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 270 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 16.9 citations a year over 16 year(s) since 2012 |
| Impact for its field and year | 3 / 6 | Cited 7.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 29 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Maria Cristina Polidori: h-index 58 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Perugia: institution h-index 747 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 22019723) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 40 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 40 of the 96 points we could judge it on is 42 out of 100. |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.bbadis.2011.10.006
- PubMed: 22019723
- Original source →
- Free full text: Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Mild cognitive impairment
Also in Mild cognitive impairment
76 studies in the library are filed under Mild cognitive impairment with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Mild cognitive impairment hub.